| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/08/2009 | WO2009004432A1 Anthelmintic combination |
| 01/08/2009 | WO2009004082A2 Anticonvulsive pharmaceutical compositions |
| 01/08/2009 | WO2008109005A3 Use of anti-cd22 immunotoxins and protein-synthesis-inhibiting chemotherapeutic agents in treatment of b cell cancers |
| 01/08/2009 | WO2008102128A3 Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid |
| 01/08/2009 | WO2008089389A3 Treatment of cancers with acquired resistance to kit inhibitors |
| 01/08/2009 | WO2008074450A3 Non-peptidic renin inhibitors nitroderivatives |
| 01/08/2009 | WO2008039863A3 Composition comprising a melanocortin receptor (mcr) modulating agent alone or in combination with a second neurogenic agent for treating nervous system disorders |
| 01/08/2009 | WO2008017331A3 Peroral drug form comprising dienogest and ethinyl estradiol for contraception |
| 01/08/2009 | US20090013420 Psmcs as Modifiers of the Rb Pathway and Methods of Use |
| 01/08/2009 | US20090012270 Ox2 receptor homologs |
| 01/08/2009 | US20090012161 Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor |
| 01/08/2009 | US20090012098 5-ht1a receptor subtype agonist |
| 01/08/2009 | US20090012065 Therapeutic applications of pro-apoptotic benzodiazepines |
| 01/08/2009 | US20090012020 Inhibiting formation of atherosclerotic lesions |
| 01/08/2009 | US20090012003 Polypeptides homologous to vegf and bmp1 |
| 01/08/2009 | US20090011989 Treating or preventing myocardial contractile dysfunction that occurs after a myocardial infarction or other structural heart disease (e.g., end-stage valve disease) by by administering CaMK11 inhibitor, a peptide having a specific sequence of amino acids; dilated cardiomyopathy; transgenic animals |
| 01/08/2009 | US20090011977 Novel Lipopeptides as Antibacterial Agents |
| 01/08/2009 | US20090011434 Methods And Compositions For Diagnosing Breast Cancer |
| 01/08/2009 | US20090010986 Polymeric gel delivery system for pharmaceuticals |
| 01/08/2009 | US20090010936 Novel Stra6 Polypeptides |
| 01/08/2009 | US20090010935 Compositions and Methods of Treating Tumors |
| 01/08/2009 | US20090010917 Targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor; apoptosis-inducing factor |
| 01/08/2009 | US20090010914 Use of Oligouronates for Treating Mucus Hyperviscosity |
| 01/08/2009 | US20090010902 TLR4 Transcription Activity Suppressor |
| 01/08/2009 | US20090010893 Treating diarrhea in dogs |
| 01/08/2009 | US20090010886 Method for the Treatment of Myeloproliferative Diseases Using(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2- Methylsulfonylethyl]-4- Acetylaminoisoindoline-1,3- Dione |
| 01/08/2009 | US20090010883 Using endothelial growth factor specific immunoglobulin as therapeutic tool in treatment of metastatic gastric or stomach cancer |
| 01/08/2009 | US20090010882 Polymorphs of sodium 4-4[(4-chloro-2-hydroxybenzoyl) amino] butanoate |
| 01/08/2009 | US20090010881 Using endothelial growth factor specific immunoglobulin as therapeutic tool in treatment of bladder cancer |
| 01/08/2009 | US20090010879 Receptor Based Antagonists and Methods of Making and Using |
| 01/08/2009 | US20090010877 Methods for treatment prostate cancer using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| 01/08/2009 | US20090010872 Chimeric soluble hyper il-11 and use thereof |
| 01/08/2009 | DE102007051090A1 Use of a serotonergic compound as a neuroprotective agent for treating focal cerebral ischemia after the development of an acute phase ischemia, for the neuro-regeneration during the treatment of neuronal disease and to treat e.g. stroke |
| 01/08/2009 | DE102007030931A1 Zusammensetzung, enthaltend mindestens einen nutritiven, mindestens einen desinfizierenden bzw. dekontaminierenden und/oder mindestens einen Proteasen hemmend wirkenden Wirkstoff und/oder Wirkstoffkomplex A composition comprising at least one nutritional, at least one disinfecting or decontaminating and / or at least one protease inhibiting active ingredient and / or active ingredient complex |
| 01/08/2009 | CA2692320A1 Methods of treating bone disorders with modulators of axl |
| 01/08/2009 | CA2691107A1 Pharmaceutical combination of nsaid and prostaglandin compound |
| 01/08/2009 | CA2691102A1 Pharmaceutical combination of opioid and prostaglandin compound |
| 01/07/2009 | EP2011883A1 Method of predicting skin spot formation and method of screening skin spot formation inhibitor with the use of spot site-increasing genes as indication |
| 01/07/2009 | EP2011517A1 Polynucleotide binding complexes comprising sterols and saponin |
| 01/07/2009 | EP2011515A1 Verwendung von Antagonisten von G Protein gekoppelten Rezeptoren (GPCRs) |
| 01/07/2009 | EP2011514A1 A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient |
| 01/07/2009 | EP2011512A1 An anti HSP90 antibody |
| 01/07/2009 | EP2011504A1 Skin cream for treatment and/or cleaning of skin for neurodermitis |
| 01/07/2009 | EP2011491A1 Anticonvulsive pharmaceutical compositions |
| 01/07/2009 | EP2011489A2 Method to inhibit ischemia and reperfusion injury |
| 01/07/2009 | EP2010217A2 Therapeutic method for glycaemic control |
| 01/07/2009 | EP2010191A2 Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines |
| 01/07/2009 | EP2010176A2 Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| 01/07/2009 | EP2010173A1 Compounds for treating pulmonary hypertension |
| 01/07/2009 | EP2010167A2 Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
| 01/07/2009 | EP2010146A1 Homeopathic composition and kit therefore |
| 01/07/2009 | EP1885386A4 Non-natural chemokine receptor ligands and methods of use thereof |
| 01/07/2009 | EP1718568A4 Process for preparing water soluble diterpenes and their applications |
| 01/07/2009 | EP1663257B1 Use of laxatives for treating irritable bowel syndrome |
| 01/07/2009 | EP1635843B1 Therapy comprising dienogest for hormone replacement and depression |
| 01/07/2009 | EP1580556B1 Functional domain and associated molecule of dock2 essentially required in lymphocyte migration |
| 01/07/2009 | EP1503737B1 Nanoparticulate nystatin formulations |
| 01/07/2009 | EP1499277B1 Pyy3-36 for the reduction or prevention of obesity |
| 01/07/2009 | EP1474434B1 The eaat2 promoter and uses thereof |
| 01/07/2009 | EP1292300B1 Combinations od dipeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment fo diabete mellitus |
| 01/07/2009 | EP1218361B1 Oxa- and thiazole derivatives useful as antidiabetic and antiobesity agents |
| 01/07/2009 | EP1115874B1 Alzheimer's disease secretase |
| 01/07/2009 | CN101341170A Antibodies against interleukin-22 binding protein and its uses |
| 01/07/2009 | CN101340947A Combination of an iap-inhibitor and a taxane7 |
| 01/07/2009 | CN101340946A Pharmaceutical combination for the treatment of luts |
| 01/07/2009 | CN101340931A Modulation of tlr-mediated immune responses using adaptor oligonucleotides |
| 01/07/2009 | CN101340908A Compositions and methods for treating cns disorders |
| 01/07/2009 | CN101337071A Composition for preparing anti-cataract products |
| 01/07/2009 | CN101336926A Anticancer composition loaded with bortezomib and alkyl agent |
| 01/07/2009 | CN101336915A Medicine combination with antitumor activity |
| 01/07/2009 | CN101336914A Medicine combination capable of reducing myocardial infarction area and use thereof |
| 01/07/2009 | CN101336898A Anticancer sustained-released formulation loaded with platinum compound and synergist thereof |
| 01/07/2009 | CN101336894A Anticancer composition containing platinum compound and bortezomib |
| 01/07/2009 | CN101336893A Sustained-released injection containing bortezomib and topology enzyme inhibitor |
| 01/07/2009 | CN101336892A Gel injection of sustained-released topology enzyme inhibitor and preparation method thereof |
| 01/07/2009 | CN101336891A Anticancer sustained-released gel injection and preparation method thereof |
| 01/07/2009 | CN101336890A Anticancer sustained-release gel injection |
| 01/07/2009 | CN101336887A Drug delivery system using subconjunctival depot |
| 01/07/2009 | CN100448994C Isolated nucleic acid molecules which encode T cell inducible factors, or interleukin-21, proteins encoded, and uses thereof |
| 01/07/2009 | CN100448487C Method of treating estrogen receptor positive carcinoma |
| 01/07/2009 | CN100448454C Cancer treatment composition and method using natural plant essential oils |
| 01/07/2009 | CN100448453C A method of treating or preventing chronic wounds and a complete nutritional composition comprising glycine and/or leucine for use therein |
| 01/07/2009 | CN100448449C [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain |
| 01/07/2009 | CN100448444C Broadspectrum heterocyclic substituted phenyl containing sulfonamide HIV protease inhibitors |
| 01/07/2009 | CN100448442C Use of elastic protease inhibitor for preparing medicine for protecting cerebral hemorrhage |
| 01/07/2009 | CN100448441C Compsn. for treatment of burns |
| 01/07/2009 | CN100448358C Oil/fat composition |
| 01/06/2009 | US7473771 Nucleotide sequences coding recombinant protein for use in prevention and treatment of hyperphosphatemia |
| 01/06/2009 | US7473761 Therapy for metabolic disorders; polycystic kidney diseasel diarrhea; gastrointestinal disorders |
| 01/06/2009 | US7473703 e.g. N-(4-{1-Hydroxy-1-[1-(2-methoxyethyl)-1H-pyrrol-2-yl]-ethyl}-phenyl)-N-methyl-benzenesulfonamide; liver X receptor (LXR) agonist; antidiabetic, antiproliferative agent; lipid, metabolic disorders, obesity, diabetes, hypercholesterolemia, atherosclerosis, hyperlipoproteinemia |
| 01/06/2009 | US7473686 Thrombopoietin mimetics |
| 01/06/2009 | US7473679 Treatments employing neuronal exocytosis-inhibiting peptides |
| 01/06/2009 | US7473420 Processing adipose tissue to deliver a concentrated amount of stem cells in a closed system so that the stem cells are not exposed to external environment by use of a pre-assembled, linked set of closed, sterile containers and tubing allowing for transfer of tissue and fluid elements within a closed path |
| 01/06/2009 | CA2486697C 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
| 01/06/2009 | CA2423017C Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases |
| 01/06/2009 | CA2400818C Antibiotic and antifungal compositions |
| 01/06/2009 | CA2387058C Injection vehicle for polymer-based formulations |
| 01/06/2009 | CA2369504C Pyrazole compositions useful as inhibitors of erk |
| 01/06/2009 | CA2348084C Crystallisation using supercritical or subcritical fluids |
| 01/06/2009 | CA2347979C Treatment of skin with adenosine or adenosine analog |